Firefly Neuroscience acquires Evoke Neuroscience
05/05/25, 12:54 PM
Location
buffalonew yorkIndustry
healthcare
medical
biotechnology
health care
Firefly Neuroscience, Inc. has acquired Evoke Neuroscience, Inc. for $6 million, with the payment split between cash and stock. This acquisition will significantly expand Firefly's database and technology portfolio in brain health assessment. The deal is expected to enhance both companies' capabilities and drive future growth. Evoke's investors may also receive an earn-out based on revenue targets.
Company Info
Location
Buffalo, New York, United States
Company info
Firefly (NASDAQ: AIFF) is an AI company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, secured patent protection, and achieved FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.